Novadip Biosciences Receives Rare Paediatric Disease Priority Review and Orphan Disease Designation
Rare Paediatric Disease Priority Review and Orphan Disease Designation
Dual designations granted for NVD-003 for the Treatment of Congenital Pseudarthrosis of the Tibia a serious and debilitating condition that primarily affects children
Walloon Region Government to support the development of treatments at Novadip with €9.4 million of non-dilutive funding
Walloon Region Minister Willy Borsus to visit Novadip Biosciences in Mont-Saint-Guibert today
Mont-Saint-Guibert, Dec 23 2020 (GlobeNewswire) - Novadip Biosciences ( Novadip ), a clinical stage company developing treatments to regenerate impaired tissues in patients with significant unmet medical needs, today announces that the U.S. Food and Drug Administration (FDA) has granted Rare Paediatric Disease designation and Orphan Drug designation for NVD-003, a cell therapy for the treatment of Congenital Pseudarthrosis of the Tibi
QuantuMDx diagnostic test for SARS-CoV-2 remains suitable for the detection of all discovered variants, including VUI-202012/01
NEWCASTLE UPON TYNE, UK, 22 December 2020. QuantuMDx Group Limited (“QuantuMDx”), a UK-based life sciences company developing transformational point-of-care molecular diagnostics, today confirms its diagnostic assay for SARS-CoV-2 remains suitable for detecting all available virus strains, following the identification of a new strain of SARS-CoV-2.
The UK COVID Genomics Consortium and Public Health England have identified a new strain of SARS-CoV-2 which is characterised by multiple spike gene variants. The new strain known as VUI-202012/01 or lineage B.1.1.7 appears to be significantly more transmissible than other circulating linages and there are reports that some diagnostic tests may be affected.
QuantuMDx Diagnostic Test for SARS-CoV-2 Remains Suitable for the Detection of All Discovered Variants, Including VUI-202012/01 koreabizwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from koreabizwire.com Daily Mail and Mail on Sunday newspapers.
(1)
QuantuMDx diagnostic test for SARS-CoV-2 remains suitable for the detection of all discovered variants, including VUI-202012/01
NEWCASTLE UPON TYNE, UK, 22 December 2020. QuantuMDx Group Limited ( QuantuMDx ), a UK-based life sciences company developing transformational point-of-care molecular diagnostics, today confirms its diagnostic assay for SARS-CoV-2 remains suitable for detecting all available virus strains, following the identification of a new strain of SARS-CoV-2.
The UK COVID Genomics Consortium and Public Health England have identified a new strain of SARS-CoV-2 which is characterised by multiple spike gene variants. The new strain known as VUI-202012/01 or lineage B.1.1.7 appears to be significantly more transmissible than other circulating linages and there are reports that some diagnostic tests may be affected.
About Faron Pharmaceuticals Oy
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen® (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen® has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine®, the Company s pipeline candidate to prevent vascular leakage and organ failures is currently being tested in